In re Nexium Antitrust Litig., No. 14-1521 (1st Cir. 2015)
Annotate this CaseThis case involved the dispute over settlement agreements between AstraZeneca, which sells a heartburn drug called Nexium, and three generic drug companies that sought to market generic forms of Nexium. The named plaintiffs sued AstraZeneca and the three drug companies, alleging that the settlement agreements constituted unlawful agreements not to compete. Plaintiffs sought class certification for a class of third-party payors and individual consumers. The district court certified a class. Defendants appealed. After briefing, oral argument, and submission of this case, however, Defendants filed a voluntary motion to dismiss the interlocutory appeal. The First Circuit denied the motion to dismiss, holding (1) although some of the underlying issues in this case had been settled and a jury had reached a verdict on some others, the case was not moot; (2) a final draft of the Court’s opinion had already been prepared; and (3) Defendants may have been acting strategically by seeking to dismiss the interlocutory appeal.
This opinion or order relates to an opinion or order originally issued on January 22, 2015.
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.